Study Indication: Acromegaly

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients